Sarepta Therapeutics Swaps $291 Million in Convertible Notes for New 2030 Debt and Cash
I'm PortAI, I can summarize articles.
Sarepta Therapeutics Inc. has exchanged $291.4 million of its 1.25% Convertible Senior Notes due 2027 for new 4.875% Convertible Senior Notes due 2030, plus $31.6 million in cash. This increases the total outstanding principal of the 2030 notes to $893.4 million. The exchange was conducted through privately negotiated agreements and the new notes were issued under an indenture with U.S. Bank Trust Company.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments